2382-10-7

Basic information

• Product Name: 2,6-DICHLORO-9-METHYL-9H-PURINE
• Synonyms: 2,6-DICHLORO-9-METHYL-9H-PURINE;2,6-Dichloro-9-Methylpurine;9-Methyl-2,6-dichloropurine
• CAS NO: 2382-10-7
• Molecular Formula: C₆H₄Cl₂N₄
• Molecular Weight: 203.03
• Mol File: 2382-10-7.mol

Chemical Properties

• Melting Point: 152-153℃
• Boiling Point: 307.2°C at 760 mmHg
• Flash Point: 139.6°C
• Appearance: /
• Density: 1.76
• Vapor Pressure: 0.000733mmHg at 25°C
• Refractive Index: 1.76
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -0.90±0.10(Predicted)
• CAS DataBase Reference: 2,6-DICHLORO-9-METHYL-9H-PURINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2,6-DICHLORO-9-METHYL-9H-PURINE(2382-10-7)
• EPA Substance Registry System: 2,6-DICHLORO-9-METHYL-9H-PURINE(2382-10-7)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 2382-10-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2,6-DICHLORO-9-METHYL-9H-PURINE is used as a reagent for the synthesis of highly selective inhibitors of PI3K-δ (Phosphoinositide 3-kinase delta). These inhibitors are crucial in the treatment of inflammatory diseases, particularly those related to leukocytes, which are white blood cells that play a vital role in the immune system. By targeting PI3K-δ, these inhibitors can help regulate the immune response and alleviate the symptoms of various leukocyte-related illnesses.

InChI:InChI=1/C6H4Cl2N4/c1-12-2-9-3-4(7)10-6(8)11-5(3)12/h2H,1H3

Upstream product

• 1198-33-0 9-methylxanthine 
• 5451-40-1 2,6-dichloro-7H-purine 
• 74-88-4 methyl iodide 
• 74-87-3 methylene chloride 
• 5451-40-1 2,6 dichloropurine 
• 74-83-9 methyl bromide 
• 69-89-6 xanthin 
• 5451-40-1 2,6-dichloropurine 

Downstream Products

• 5502-78-3 9-Methylguanine 
• 101622-53-1 2-chloro-6-benzylamino-9-methylpurine 
• 30720-65-1 2,6-Diamino-9-methylpurine 
• 925254-29-1 2-chloro-N-cyclohexyl-9-methyl-9H-purin-6-amine 
• 1062592-41-9 (2-chloro-9-methyl-9H-purin-6-yl)-(4-chloro-phenyl)-amine 
• 1055926-73-2 1,1-dimethylethyl 2-(2-chloro-9-methyl-9H-purin-6-yl)-2-cyclo-hexyl-hydrazine-carboxylate 
• 1148003-33-1 2-chloro-9-methyl-6-morpholino-9H-purine-8-carbaldehyde 
• 1257378-51-0 C₂₅H₃₆N₈O₂ 
• 1148003-35-3 4-(2-chloro-9-methyl-9H-purin-6-yl)morpholine 
• 1402821-28-6 (R)-2-(6-(biphenyl-4-ylmethylamino)-9-methyl-9H-purin-2-ylamino)butan-1-ol 
• 1402821-29-7 (R)-2-(6-(diphenylmethylamino)-9-methyl-9H-purin-2-ylamino)butan-1-ol 
• 1402821-30-0 (R)-2-(9-methyl-6-(phenethylamino)-9H-purin-2-ylamino)butan-1-ol 
• 288305-89-5 (R)-6-(benzylamino)-2-[[(1-hydroxymethyl)propyl]amino]-9-methylpurine 
• 1402821-31-1 (R)-2-(9-methyl-6-(phenylamino)-9H-purin-2-ylamino)butan-1-ol 

Relevant articles and documents

Purine-based Ir(iii) complexes for sensing viscosity of endo-plasmic reticulum with fluorescence lifetime imaging microscopy

Novel purine-based iridium complexes were designed for selective determination of ER viscosity. TheIr-PHpossessed excellent ER targeting ability and could distinguish the viscosity changes under ER stress by fluorescence lifetime image microscopy (FLIM),

Regioselective alkylation reaction of purines under microwave irradiation

The alkylation of purines which is generally carried out after anion formation by treatment with a base and alkyl halide is complicated and in the best cases, mixtures of N-alkylated compounds are obtained. Purine derivatives can be acquired from alkylati

Structure-Based Optimization of Quinazolines as Cruzain and TbrCATL Inhibitors

The cysteine proteases, cruzain and TbrCATL (rhodesain), are therapeutic targets for Chagas disease and Human African Trypanosomiasis, respectively. Among the known inhibitors for these proteases, we have described N4-benzyl-N2-phenylquinazoline-2,4-diamine (compound 7 in the original publication, 1a in this study), as a competitive cruzain inhibitor (Ki = 1.4 μM). Here, we describe the synthesis and biological evaluation of 22 analogs of 1a, containing modifications in the quinazoline core, and in the substituents in positions 2 and 4 of this ring. The analogs demonstrate low micromolar inhibition of the target proteases and cidal activity against Trypanosoma cruzi with up to two log selectivity indices in counterscreens with myoblasts. Fourteen compounds were active against Trypanosoma brucei at low to mid micromolar concentrations. During the optimization of 1a, structure-based design and prediction of physicochemical properties were employed to maintain potency against the enzymes while removing colloidal aggregator characteristics observed for some molecules in this series.

Purine derivative free radical precursor molecule and preparation method thereof

The invention provides a structure of a purine derivative free radical precursor molecule, which is an organic N-type dopant small molecule material. The invention also provides a method for preparingsuch a purine derivative free radical precursor molecule. The invention provides a new development direction for the research on organic N-type dopants in the field of organic conductive or semiconductor materials.

Discovery of novel 9H-purin derivatives as dual inhibitors of HDAC1 and CDK2

HDAC and CDK inhibitors have been demonstrated to be synergistically in suppressing cancer cell proliferation and inducing apoptosis. In this work, we incorporated the pharmacophore groups of HDACs and CDKs inhibitors into one molecule to design and synthesize a series of purin derivatives as HDAC/CDK dual inhibitors. The lead compound 6d, showing good HDAC1 and CDK2 inhibitory activity with IC50 values of 5.8 and 56 nM, respectively, exhibited attractive potency against several cancer cell lines in vitro. This work may lead to the discovery of a novel scaffold and potential dual HDAC/CDK inhibitors.

SUBSTITUTED BICYCLIC PYRIMIDINE-BASED COMPOUNDS AND COMPOSITIONS AND USES THEREOF

Novel C-2-substituted bicyclic compounds of Formula I have been prepared and found to be useful as potent inhibitors of hGGPPS by inhibiting geranylgeranylation of proteins and inhibiting the biosynthesis of GGPP. The application is directed to these compounds, to compositions comprising these compounds, and to their use, in particular as medicaments for use in the treatment of cancer and other conditions which are treatable by inhibiting human geranylgeranylation pyrophosphate hGGPPS activity.

Discovery of 9H-purins as potential tubulin polymerization inhibitors: Synthesis, biological evaluation and structure?activity relationships

Two series of N-(4-methoxyphenyl)-N-methyl-9H-purin-6-amines (9a-d and 10a-h) and 9-substituted benzyl-6-chloro-9H-purines (11a-h) were designed and synthesized. Their antiproliferative activities against human myelogenous leukemia (K562), human neuroblas

PYRAZOLYLAMINOPURINES AS ITK INHIBITORS

Provided are pyrazolylaminopurine compounds that are inhibitors of ITK kinase, compositions containing these compounds and methods for treating diseases mediated by ITK kinase. In particular, provided are compounds of Formula I or II, stereoisomers, tauto

COMPOUNDS FOR IMPROVING MRNA SPLICING

Provided herein are compounds useful for improving mRNA splicing in a cell. Exemplary compounds provided herein are useful for improving mRNA splicing in genes comprising at least one exon ending in the nucleotide sequence CAA. Methods for preparing the compounds and methods of treating diseases of the central nervous system are also provided.

CALCIUM CHANNEL AGONISTS

Embodiments of calcium channel agonists, as well as methods of making and using the calcium channel agonists, are disclosed. The disclosed calcium channel agonists and corresponding salt forms have a structure according to general formula I wherein each bond depicted as " " is a single bond or a double bond as needed to satisfy valence requirements; Z1, Z2, Z3, Z4, and Z5 independently are nitrogen or carbon; R1 and R3 are alkyl; R2 is alkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl; and R4 is alkyl or hydroxyalkyl.